Drug Trial Radar · NCT00800605
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
Last checked: Nov 20, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,250
Actual
Start
Dec 2008
Primary completion
May 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- Alachua Government Services, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 2, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 49 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the efficacy of an investigational Vero cell-derived, trivalent, seasonal influenza vaccine to prevent infection with an influenza virus that is antigenically similar to one of the three strains in the vaccine. Subjects will be randomized in a double-blind fashion to receive a single intramuscular injection of either the investigational vaccine or placebo. Blood will be drawn from all subjects for a determination of hemagglutination inhibition antibody titers on Days 0 and 21, body temperature and injection site reactions will be monitored daily for 7 days. In addition, subjects must return to the clinic promptly to have swab samples of their nose and throat taken whenever they feel flu symptoms and all subjects will be monitored for adverse events until Day 180.
Conditions
- Influenza
Interventions
Vero cell-derived, trivalent, seasonal influenza vaccineBiological
Single intramuscular injection
Placebo: Phosphate-buffered salineBiological
Single intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of an Investigational Vero Cell-derived Influenza Vaccine to Prevent Infection With an Influenza Virus That is Antigenically Similar to One of the Three Strains in the VaccineTime frame: 180 days
Locations
36 sites in 1 country. Site status is shown where the registry gives one.
Quality of Life Medical & Research Center, LLC
Tucson, Arizona
Benchmark Research
Sacramento, California
California Research Foundation
San Diego, California
Benchmark Research San Francisco
San Francisco, California
Radiant Research, Inc
Denver, Colorado
Clinical Research of South Florida
Coral Gables, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Pharmax Research Clinic
Miami, Florida
University Clinical Research, Inc
Pembroke Pines, Florida
Miami Research Associates
South Miami, Florida
Clinical Research Atlanta
Stockbridge, Georgia
Radiant Research, Inc - Chicago
Chicago, Illinois
Johnson County Clin-Trials
Lenexa, Kansas
Vince and Associates Clinical Research
Overland Park, Kansas
Central Kentucky Research Associates, Inc.
Lexington, Kentucky
Benchmark Research
Metairie, Louisiana
Center for Pharmaceutical Research
Kansas City, Missouri
Radiant Research, Inc.
St Louis, Missouri
Sundance Clinical Research
St Louis, Missouri
Meridian Clinical Research, LLC
Omaha, Nebraska
Regional Clinical Research, Inc.
Endwell, New York
Rochester Clinical Research, Inc.
Rochester, New York
Triangle Medical Research Associates
Raleigh, North Carolina
Wake Research Associates, LLC
Raleigh, North Carolina
Radiant Research - Cincinnati
Cincinnati, Ohio
Omega Medical Research
Warwick, Rhode Island
Spartanburg Medical Research
Spartanburg, South Carolina
Health Concepts
Rapid City, South Dakota
Clinical Research Associates, Inc. - Nashville
Nashville, Tennessee
Benchmark Research Austin
Austin, Texas
Benchmark Research Ft. Worth
Fort Worth, Texas
Benchmark Research San Angeolo
San Angelo, Texas
Jean Brown Research / Westside Medical
Salt Lake City, Utah
Advanced Clinical Research
West Jordan, Utah
PI-COOR Clinical Research
Burke, Virginia
Clinical Research Associates of Tidewater
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.